Mechanistically, the risk factor hypertension for a severe COVID-19 course, could be linked to the use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) to treat patients with hypertension. This evidence concerns the gene ACE and hypertensive disorder.